Junliang Li

Junliang Li


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Cancer Letters
Verified
Journal Article
Open access
ZLZhipeng Ling
Zhipeng Ling
JPJunping Pan
Junping Pan
ZZZhongfei Zhang
Zhongfei Zhang
GCGuisi Chen
Guisi Chen
JGJiayuan Geng
Jiayuan Geng
JLJunliang Li
Junliang Li
Glioblastoma (GBM), one of the most malignant brain tumors in the world, has limited treatment options and a dismal survival rate. Effective and safe disease-modifying drugs for glioblastoma are urgently needed. Here, we identified a small molecule, Molephantin (EM-5), effectively penetrated the blood-brain barrier (BBB) and demonstrated notable antitumor effects against GBM with good safety profiles both in vitro and in vivo. Mechanistically, EM-5 not only inhibits the proliferation and invasion of GBM cells but also induces cell apoptosis through the reactive oxygen species (ROS)-mediated PI3K/Akt/mTOR pathway. Furthermore, EM-5 causes mitochondrial dysfunction and blocks mitophagy flux by impeding the fusion of mitophagosomes with lysosomes. It is noteworthy that EM-5 does not interfere with the initiation of autophagosome formation or lysosomal function. Additionally, the mitophagy flux blockage caused by EM-5 was driven by the accumulation of intracellular ROS. In vivo, EM-5 exhibited significant efficacy in suppressing tumor growth in a xenograft model. Collectively, our findings not only identified EM-5 as a promising, effective, and safe lead compound for treating GBM but also uncovered its underlying mechanisms from the perspective of apoptosis and mitophagy.

1 February 2018 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
WCWei Chen
Wei Chen
KKKuan-Kei Kong
Kuan-Kei Kong
XXXin-Ke Xu
Xin-Ke Xu
CCCheng Chen
Cheng Chen
HLHui Li
Hui Li
FLFang-cheng Li
Fang-cheng Li
Glioblastoma (GBM) is the most common type of malignant brain tumor. In spite of recent advancements in surgical techniques, chemotherapy, and radiation therapy, patients with GBM often face a dire prognosis. MicroRNAs have been shown to modulate the aggressiveness of various cancers, and have emerged as possible therapeutic agents for the management of GBM. miR-205 is dysregulated in glioma and act as a prognostic indicator. However, the role of miR-205 in the development of GBM has not been elucidated. To better understand the pathogenesis of GBM, we examine the biological significance and molecular mechanisms of miR-205 in GBM cells. Zinc finger E-box binding homeobox 1 (ZEB1) has been shown to regulate the epithelial-mesenchymal transition (EMT), which is strongly associated with GBM malignancy. In the present study, we show miR-205 expression is reduced in GBM tissues and cell lines, and ZEB1 expression is inversely correlated with miR-205 expression. We also show ZEB1 is a downstream target of miR-205 and the Akt/mTOR signaling pathway is activated when miR-205 interacts with ZEB1. Increased activity of miR-205 in GBM cells significantly inhibits migration and invasion, and prevents EMT. Furthermore, overexpression of ZEB1 partially abolishes these inhibitory effects of miR-205. We show that miR-205 negatively regulates the expression of ZEB1 in GBM, inhibits cell migration and invasion, and prevents EMT, at least in part through the inhibition of the activation of the Akt/mTOR signaling pathway. Our results indicate miR-205 may be an efficacious therapeutic agent in the treatment of GBM.

1 June 2021 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
ZZZheng Zhang
Zheng Zhang
ZWZijian Wang
Zijian Wang
ZLZhipeng Ling
Zhipeng Ling
YLYu Li
Yu Li
JPJunping Pan
Junping Pan
FXFei Xiao
Fei Xiao

1 January 2023 in Open Life Sciences
Verified
Journal Article
Open access
PDF file
JQJun Qiu
Jun Qiu
HWHaoyun Wang
Haoyun Wang
XLXin Lv
Xin Lv
LMLipeng Mao
Lipeng Mao
JHJunyan Huang
Junyan Huang
HJHaiping Jiang
Haiping Jiang
The aim of this study is to explore a novel classification and investigate the clinical significance of hepatocellular carcinoma (HCC) cells. We analyzed integrated single-cell RNA sequencing and bulk RNA-seq data obtained from HCC samples. Cell trajectory analysis divided HCC cells into three subgroups with different differentiation states: state 1 was closely related to phosphoric ester hydrolase activity, state 2 was involved in eukaryotic initiation factor 4E binding, translation regulator activity and ribosome, and state 3 was associated with oxidoreductase activity and metabolism. Three molecular classes based on HCC differentiation-related genes (HDRGs) from HCC samples were identified, which revealed immune checkpoint gene expression and overall survival (OS) of HCC patients. Moreover, a prognostic risk scoring (RS) model was generated based on eight HDRGs, and the results showed that the OS of the high-risk group was worse than that of the low-risk group. Further, potential therapeutic drugs were screened out based on eight prognostic RS-HDRGs. This study highlights the importance of HCC cell differentiation in immunotherapy, clinical prognosis, and potential molecular-targeted drugs for HCC patients, and proposes a direction for the development of individualized treatments for HCC.

7 October 2026 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
ZLZhipeng Ling
Zhipeng Ling
JPJunping Pan
Junping Pan
XXXianglu Xiao
Xianglu Xiao
WWWenfan Wu
Wenfan Wu
GCGuisi Chen
Guisi Chen
YZYubo Zhang
Yubo Zhang
Defective mitophagy is a key pathological risk of Alzheimer’s disease (AD), yet available pharmacological agents capable of restoring mitophagy remain clinically limited, largely due to the lack of tools for drug screening and target identification. To address this, we introduce an integrated platform with three novel artificial intelligence (AI)-enabled approaches—the phenotype-based screening model ‘CellAutoFM’, the drug-likeness predictor ‘ADMET Ranker’, and the target deconvolution method ‘PROCAT’. Using this platform together with wet lab validation, Crassifolin A (JGX-1) is identified as a potent natural product-derived mitophagy inducer; structurally, JGX-1 directly binds to ATP-binding cassette sub-family A member 1 (ABCA1) and sub-family G member 1 (ABCG1), triggering enhanced cholesterol efflux which activates PINK1/Parkin-dependent mitophagy. In both in vitro and in vivo AD laboratory models, JGX-1 reduces amyloid-β and Tau pathologies in an autophagy/mitophagy-dependent manner as these benefits are dramatically blunted with key mitophagy genes knocked down. Collectively, we provide an open-access, reproducible AI-assisted platform for rapid compound screening, drug-likeness evaluation, and potential target prediction to advance drug discovery. Through this paradigm, we unveil modulating the ABCA1/ABCG1-mediated cholesterol-mitophagy pathway as a promising anti-AD strategy, with a novel drug candidate JGX-1 identified.